Dr. Karim Galil was drained. He had been tired of losing patients to cancer. He had been tired of cluttered medical records. And he was tired of trying to stay on top of this avalanche of clinical trials touting one solution or another. Losing both patience and too many patients, Galil decided to make a organized and artificially intelligent system to match people under his care with thegreatest diagnostic and treatment procedures available.
He called his new system Mendel.ai after Gregor Mendel, the father of modern genetics science, and has just increased $2 million in seed funding from DCM Ventures, Bootstrap Labs and Launch Capitalto get the project off the ground.
Mendel.ai is similar in several ways to this U.K.-based BenevolentBio, which is centered on skimming through scientific papers to locate the latest in cutting-edge medical study. But instead than using keyword data, Mendal.ai uses analgorithm that knows the unstructured, natural language content in medical documents pulled from clinicaltrials.gov,and then compares it to your patients medical record. The investigation procedure returns a completely personalized match and assesses the patients eligibility for each suggested treatment in minutes, according to Galil.
The startup could prove useful for physicians thatincreasingly find it hard to keep up on the exhaustive number of clinical data.
Patients can also be overwhelmed at the possibility of combing through mountains of clinical trial study. A lung cancer patient, as an example, might find 500 potential trials on clinicaltrials.gov, each one of which has a unique, thorough list of eligibility criteria that must be read and assessed, says Galil. As this pool of trials changes each week, it is humanly impossible to keep track of all excellent matches.
Mendel.ai seeks to decrease the time it takes and thus save more lives. The business is presently integrating with the Comprehensive Blood & Cancer Center (CBCC) at Bakersfield, Calif, which will allow the centers physicians to rapidly meet their patients with clinical trials within a couple of minutes, according to Galil.
The strategy going forward is to functionwith hospitals and cancer genomics businesses like the CBCC to improve Mendel.ai and present the system. A more immediate goal, Galil says, would be challenging IBMs Watson against his system to determine which one can match the patients up better.
This is the distinction between somebody dying and somebody alive. Its not a joke, Galil told TechCrunch.